ResearchSafe

Retatrutide hitting 30% in Phase 3, does this change the practical protocol

Posted by tiredmira in Weight Loss & Metabolic - 4 points, 6 comments.

https://www.axios.com/2026/06/03/obesity-drug-race-patient-benefits

Lilly's triple agonist retatrutide just posted around 30% weight loss in Phase 3, which is honestly kind of wild compared to what most people see on sema or tirz.

For me this raises the obvious question of whether the ceiling matters if real-world adherence is the bottleneck. Like, I track my HRV and sleep and food logs religiously, and even with sema I have to actively work at keeping protein and steps up. A stronger drug sounds great until you realize the side effect burden scales too, and titration gets way more annoying.

Curious what people here actually think, is a 30% number enough to switch once retatrutide is available, or is adherence and GI tolerance still going to be the real limiting factor? Also wondering how this compares to what people are seeing on tirz in practice, because the trial numbers don't always match what shows up in my logs 😅

Comments

  • patient_codes: I’ve been on tirz for about six months and the weight loss stuck around 15% for me, but the real battle has been keeping my protein up and my steps consistent when nausea hits. Even with a stronger molecule like retatrutide, I suspect the titration phase would just drag out those GI rough days, and that’s where most people fall off. For me, the practical protocol still hinges on how tolerable the dose escalation feels day to day, if I can’t keep my HRV stable or sleep decent, the extra percent l
  • elle_z: Yeah honestly the titration thing is the bit everyone glosses over. When i was ramping tirz the weeks around dose changes were pretty rough, food was the last thing i wanted and my training tanked with it. If retatru drags that out longer i cant see myself sticking it 😅 the slower the schedule the more your whole routine falls apart around it.
  • rational_coldplunge: Yeah the titration thing is the whole ballgame imo. A stronger ceiling only helps if you can actually stay on it, and GI stuff tends to be where people tap out, not the number on the scale. Tolerability basically sets the floor here.
  • tiredmira: 7mg sema. The ceiling wasn't the issue, it was the two weeks of nausea that almost made me quit. I jumped back down and the loss kept coming, just slower. So I'm basically with you, tolerability sets the floor, and I'd rather lose 18% comfortably than white-knuckle 30%. Do you think the slower titration schedule Lilly keeps hinting at actually fixes that, or is it just marketing?
  • tiredmira: Ugh yes, the dose change weeks were exactly where my HRV would crater and my sleep would get weird too. Training tanking tracks for me as well, like there's a real lag between when the nausea fades and when my appetite actually comes back normally. Did your training bounce back after each ramp step or did it just kinda stay flat until you were at a stable dose?
  • tiredmira: My hesitation is basically what you described. I did okay on sema but the 1.7 push wiped me out for like two weeks, and I won't really commit to retatrutide unless I can stay functional through titration. The 15% on tirz matches what I've seen in my own logs too, so a 30% number is huge on paper but I'm skeptical it survives real-world dosing 🥗

Community discussion - research and educational context only. Not medical advice.